WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced…
Adagio Therapeutics Announces Pricing of Initial Public Offering
Share this article
More News



Bitcoin drops 18% in seven days, breaking its summer low
November 21, 2026

Crypto Fear Reaches Extreme Levels as Bitcoin Plummets to $55K
November 21, 2026



Santiment Reveals the 5 Most Discussed Topics in Crypto This Week
November 21, 2026